to satisfy differing regulatory requirements across countries for the same therapy directed to the same disease with no obvious added benefits-resources that could otherwise be spent on discovery. Most importantly, enhanced collaboration and coordination would benefit patients by ensuring that the best possible science, standards, and practice drive the regulatory process, resulting in improved safety, innovation, and access.
To their credit, regulatory authorities and their leaders are increasingly attuned to these concerns. Progress is being made and solutions sought. Regulatory authorities are working more frequently with each other, sharing inspection and safety information, and even conferring over discrete product approvals. Various bilateral and multilateral arrangements seek to enhance collaboration, learning, and sharing of best practices as well as efforts to strengthen the regulatory science that underlies regulation and oversight. Organizations such as the International Council on Harmonization (ICH), the Pharmaceutical Inspection Convention, and Pharmaceutical Inspection Co-operation Scheme (PIC/S) have proved valuable in establishing standards and guidelines for operational alignment across a range of nations. Of note, the International Coalition of Medicines Regulatory Authorities (ICMRA) is a recently established, voluntary leadership group at the highest levels (heads of medicines regulatory authorities) intended to create a broad, formal framework with which to enhance communication, collaboration, and regulatory alignment among regulatory authorities. Nevertheless, none of these entities have the authority to ensure, nor do any of these efforts promise, greater harmonized legislation that governs regulatory entities worldwide.
The need for more drug regulatory harmonization has never been greater-or more possible. Yet the nature of bureaucracy often maintains the status quo. Absent top-down impetus, transformation can be slow. Such seminal change needs to be driven by governments that recognize the advantages to linking arms and are willing to drive harmonization forward urgently. For almost all regulatory authorities-big and small, established or fledgling-greater commitment to regulatory systems and their harmonization at the senior political level is needed to redress unclear or missing legislative mandates as well as resource issues. There have been other such moments in innovation history, including with the railroad systems and civil aviation. In each of these cases, the risk of disharmonization was evident, with well-publicized cases of accidents and near misses, such that the imperative to align across borders to protect consumers became a cri de coeur.
The regulation of drugs can either grease the wheels of progress or throw a wrench in the works. We believe that harmonized drug regulation has the potential to be the unsung hero in driving improved health along with global economic and social development. We would challenge governments, including congresses and parliaments, presidents and prime ministers, to put harmonization on their agendas and those of the G-8 or G-20 as a critical and transformative next step in advancing public health for all.
-Elias Zerhouni and Margaret Hamburg

